Late Breaking Abstract Parallel Session 1

Nov 10 2025
Convention Center: Hall A (General Session), Concourse Level
2:00 PM - 3:30 PM
Live Streamed
Captured

World Class Speakers

Mazen Noureddin
Abstract Presenter

Mazen Noureddin

Houston Research Institute and Houston Methodist Hospital
Neehar D. Parikh, MD, MS, FAASLD
Abstract Presenter

Neehar D. Parikh, MD, MS, FAASLD

University of Michigan Medical Center
Emma L. Culver, MD; PhD
Abstract Presenter

Emma L. Culver, MD; PhD

Translational Gastroenterology and Liver Unit, Uni of Oxford
Jörn M Schattenberg, MD
Abstract Presenter

Jörn M Schattenberg, MD

Saarland University Medical Center Homburg
Rotonya M. Carr, MD, FACP, FAASLD
Moderator

Rotonya M. Carr, MD, FACP, FAASLD

University of Washington
Debbie L Shawcross, BSc, MBBS, PhD, FRCP
Moderator

Debbie L Shawcross, BSc, MBBS, PhD, FRCP

Roger Williams Institute of Liver Studies

Description

Late-Breaking Abstract Parallel sessions feature oral presentations from the authors of cutting-edge, highly-rated abstracts submitted for presentation at The Liver Meeting.

Presentations

2:00 PM - 2:15 PM
Apr 29 2026
Washington, D.C.

HU6 Oral Investigational Therapy Reduces Liver Fat and Improves Adiposity Markers in Adults with MASH: Topline Results from a Phase 2 Randomized Placebo-Controlled Trial (M-ACCEL)

Mazen Noureddin , Abstract Presenter
2:15 PM - 2:30 PM
Apr 29 2026
Washington, D.C.

A Blood-Based Combined Methylation and AFP Test for Early Detection of Hepatocellular Carcinoma in At-Risk Population: Validation and Performance

Neehar D. Parikh, MD, MS, FAASLD , Abstract Presenter
3:00 PM - 3:15 PM
Apr 29 2026
Washington, D.C.

Safety and Efficacy of Inebilizumab in IgG4 Related Disease in Participants with Hepatic, Pancreatic, and Biliary Involvement: Results from the Phase 3 MITIGATE Trial

Emma L. Culver, MD; PhD , Abstract Presenter
2:30 PM - 2:45 PM
Apr 29 2026
Washington, D.C.

Long-term treatment with elafibranor leads to biochemical and symptomatic improvements for at least 3 years in patients with primary biliary cholangitis

Jörn M Schattenberg, MD , Abstract Presenter

Objectives

  • Discuss cutting-edge research into a variety of liver-related conditions, including MASLD/MASH, HCC, and PBC.